Trial of Andexanet Alfa in ICH Patients Receiving an Oral FXa Inhibitor

Open to people ages 18 years and up

1. Written informed consent. Either the patient or his or her medical proxy (or legally authorized representative if permissible by local or regional laws and regulations) has been adequately informed of the nature and risks of the study and has given written informed consent prior to Screening.
2. Deferred consent procedure is allowed where approved by local ethics committees. In cases of deferred consent, the time of the study physician's documented decision to include the patient into the study will serve as "time of consent" with respect to protocol-specific procedures.
3. In all cases where the patient does not sign informed consent prior to study entry, informed consent from the patient will be obtained as soon as realistically possible after inclusion in the trial and in accordance with the Declaration of Helsinki, International Conference on Harmonization-Good Clinical Practice (GCP), the Data Protection Directive (Directive 95/46/EC) and national and local regulations.
4. Age ≥ 18 years old at the time of consent.
5. An acute intracerebral bleeding episode, defined as an estimated blood volume ≥ 0.5 to ≤ 60 mL acutely observed radiographically within the cerebrum. Patients may have extracerebral (e.g., subdural, subarachnoid, epidural) or extracranial (e.g., gastrointestinal, intraspinal) bleeding additionally, but the intracerebral hemorrhage must be considered the most clinically significant bleed at the time of enrollment.
6. Performance of a head CT or MRI scan demonstrating the intracerebral bleeding within 2 hours prior to randomization (the baseline scan may be repeated only once to meet this criterion).
7. Treatment with an oral FXa inhibitor (apixaban [last dose 2.5 mg or greater], rivaroxaban [last dose 10 mg or greater], edoxaban [last dose 30 mg or greater], or enoxaparin [last dose 1 mg or greater]):
8. ≤ 15 hours prior to randomization.
9. > 15 hours prior to randomization or unknown time of last dose, if documented anti fXa activity is > 100 ng/mL for direct fXa inhibitors (apixaban, rivaroxaban or edoxaban) or > 0.5 IU/mL for enoxaparin may be enrolled, irrespective of the time of the last dose, and the patient is within 2 hours prior to consent. Note: Patients enrolled in this manner should receive a high andexanet dosing regimen.
10. Time from bleeding symptom onset < 6 hours prior to the baseline imaging scan. Time of trauma (if applicable) or time last seen normal may be used as surrogates for time of symptom onset. (If the baseline scan is repeated to meet Inclusion Criterion #4, the time from bleeding symptom onset must be < 6 hours prior to the repeat baseline imaging scan.)
11. Female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol-specified guidance for avoiding pregnancy for 30 days after the last dose of study drug.
12. Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential).
13. NIHSS score ≤ 35 at the time of consent.

If a patient meets any of the following criteria, he or she is not eligible to participate in this trial:

1. Planned surgery, including Burr holes for hematoma drainage, within 12 hours after randomization. Minimally invasive surgery/procedures not directly related to the treatment of intracranial bleeding and that are not expected to significantly affect hematoma volume are allowed (e.g., Burr holes for intracranial pressure monitoring, endoscopy, bronchoscopy, central lines-Section 7.3 and Appendix G).
2. GCS score < 7 at the time of consent. If a patient is intubated and/or sedated at the time of consent, they may be enrolled if it can be documented that they were intubated/sedated for non-neurologic reasons within 2 hours prior to consent.
3. Purposefully left blank.
4. Anticipation that the baseline and follow up brain scans will not be able to use the same imaging modalities (i.e., patients with a baseline CT scan should have a CT scan in follow up; similarly, for MRI).
5. Expected survival of less than 1 month (not related to the intracranial bleed).
6. Recent history (within 2 weeks) of a diagnosed TE or clinically relevant symptoms of the following:

○ Venous Thromboembolism (VTE: e.g., deep venous thrombosis, PE, cerebral venous thrombosis), myocardial infarction (MI), Disseminated Intravascular Coagulation (DIC), cerebral vascular accident, transient ischemic attack (TIA), acute coronary syndrome, or arterial systemic embolism.

1. Acute decompensated heart failure or cardiogenic shock at the time of randomization.
2. Severe sepsis or septic shock at the time of randomization.
3. The patient is a pregnant or lactating female.
4. . Receipt of any of the following drugs or blood products within 7 days prior to consent:
5. VKA (e.g., warfarin).
6. Dabigatran.
7. PCC (e.g., KCentra®) or rfVIIa (e.g., NovoSeven®), or anti-inhibitor coagulant complex (e.g., FEIBA®), FFP, and whole blood.
8. . Past use of andexanet (or planned use of commercial andexanet).
9. . Treatment with an investigational drug < 30 days prior to consent.
10. . Any tumor-related bleeding.
11. . Known hypersensitivity to any component of andexanet.